CANbridge Pharmaceuticals Inc. Secures Marketing Approval for Velaglucerase-beta (Gaurunning, CAN103) in China for Gaucher Disease Treatment

Reuters

05-20

CANbridge Pharmaceuticals Inc. Secures Marketing Approval for Velaglucerase-beta (Gaurunning, CAN103) in China for Gaucher Disease Treatment

CANbridge Pharmaceuticals Inc., a global biopharmaceutical company based in the People's Republic of China, has announced that its drug, velaglucerase-beta for injection (Gaurunning, CAN103), has received marketing approval from the National Medical Products Administration (NMPA) of the PRC. The approval, granted on May 15, 2025, allows the use of the drug for the treatment of type I and III Gaucher disease. CANbridge Pharmaceuticals holds the global proprietary rights to develop and commercialize this product. Despite this significant milestone, the company cautions that there is no guarantee of successful commercialization. The company remains dedicated to advancing transformative therapies for rare diseases, with a robust pipeline addressing unmet needs in various conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Canbridge Pharmaceuticals Inc. published the original content used to generate this news brief on May 20, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2536669370"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2536669370\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2536669370?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-20 12:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2536669370","market":"us","top_or_hot":-1,"title":"CANbridge Pharmaceuticals Inc. Secures Marketing Approval for Velaglucerase-beta (Gaurunning, CAN103) in China for Gaucher Disease Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CANbridge Pharmaceuticals Inc. Secures Marketing Approval for Velaglucerase-beta (Gaurunning, CAN103) in China for Gaucher Disease Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CANbridge Pharmaceuticals Inc., a global biopharmaceutical company based in the People's Republic of China, has announced that its drug, velaglucerase-beta for injection (Gaurunning, CAN103), has received marketing approval from the National Medical Products Administration (NMPA) of the PRC. The approval, granted on May 15, 2025, allows the use of the drug for the treatment of type I and III Gaucher disease. CANbridge Pharmaceuticals holds the global proprietary rights to develop and commercialize this product. Despite this significant milestone, the company cautions that there is no guarantee of successful commercialization. The company remains dedicated to advancing transformative therapies for rare diseases, with a robust pipeline addressing unmet needs in various conditions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Canbridge Pharmaceuticals Inc. published the original content used to generate this news brief on May 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CANbridge Pharmaceuticals Inc. Secures Marketing Approval for Velaglucerase-beta (Gaurunning, CAN103) in China for Gaucher Disease Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCANbridge Pharmaceuticals Inc. Secures Marketing Approval for Velaglucerase-beta (Gaurunning, CAN103) in China for Gaucher Disease Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-20 12:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CANbridge Pharmaceuticals Inc. Secures Marketing Approval for Velaglucerase-beta (Gaurunning, CAN103) in China for Gaucher Disease Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CANbridge Pharmaceuticals Inc., a global biopharmaceutical company based in the People's Republic of China, has announced that its drug, velaglucerase-beta for injection (Gaurunning, CAN103), has received marketing approval from the National Medical Products Administration (NMPA) of the PRC. The approval, granted on May 15, 2025, allows the use of the drug for the treatment of type I and III Gaucher disease. CANbridge Pharmaceuticals holds the global proprietary rights to develop and commercialize this product. Despite this significant milestone, the company cautions that there is no guarantee of successful commercialization. The company remains dedicated to advancing transformative therapies for rare diseases, with a robust pipeline addressing unmet needs in various conditions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Canbridge Pharmaceuticals Inc. published the original content used to generate this news brief on May 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01228","symbol_name":"北海康成-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nNDL7tFCFL:1","article_id":"2536669370","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2536669370","pubTimestamp":1747715047,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CANbridge Pharmaceuticals Inc. Secures Marketing Approval for Velaglucerase-beta  in China for Gaucher Disease Treatment. CANbridge Pharmaceuticals Inc., a global biopharmaceutical company based in the People's Republic of China, has announced that its drug, velaglucerase-beta for injection , has received marketing approval from the National Medical Products Administration  of the PRC. The approval, granted on May 15, 2025, allows the use of the drug for the treatment of type I and III Gaucher disease. CANbridge Pharmaceuticals holds the global proprietary rights to develop and commercialize this product. Despite this significant milestone, the company cautions that there is no guarantee of successful commercialization. The company remains dedicated to advancing transformative therapies for rare diseases, with a robust pipeline addressing unmet needs in various conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUB","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01228":"北海康成-B","BK1161":"生物科技"},"translate_title":"CANbridge Pharmaceuticals Inc.在中国获得Velaglucerase-beta（Gaurunning，CAN103）用于治疗戈谢病的上市许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01228":0.9},"content_text":"CANbridge Pharmaceuticals Inc. Secures Marketing Approval for Velaglucerase-beta (Gaurunning, CAN103) in China for Gaucher Disease Treatment\n    \n\n        CANbridge Pharmaceuticals Inc., a global biopharmaceutical company based in the People's Republic of China, has announced that its drug, velaglucerase-beta for injection (Gaurunning, CAN103), has received marketing approval from the National Medical Products Administration (NMPA) of the PRC. The approval, granted on May 15, 2025, allows the use of the drug for the treatment of type I and III Gaucher disease. CANbridge Pharmaceuticals holds the global proprietary rights to develop and commercialize this product. Despite this significant milestone, the company cautions that there is no guarantee of successful commercialization. The company remains dedicated to advancing transformative therapies for rare diseases, with a robust pipeline addressing unmet needs in various conditions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Canbridge Pharmaceuticals Inc. published the original content used to generate this news brief on May 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}